Skip to main content
SpringerLink
Log in

Kidney Cancer

  • Chapter
  • First Online:
Geriatric Urology

Abstract

The increased use of abdominal imaging has contributed to a rise in the incidence of kidney tumors. Notably the greatest increase has been in small renal masses among older adults. This has led to a treatment dilemma given the unclear impact of these small tumors on life expectancy, particularly in patients with advanced age or multiple comorbidities. This has contributed to the development of minimally invasive treatment approaches as well as the use of active surveillance for this disease. This chapter provides a concise review of the epidemiology, etiology, diagnosis, and treatment of kidney cancer, with particular focus on elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts and Figures 2011. American Cancer Society (2011). Accessed 17 Aug 2011.

    Google Scholar 

  2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.

    Article  PubMed  Google Scholar 

  3. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6 Pt 1):2353–8.

    Article  PubMed  Google Scholar 

  4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.

    Article  CAS  PubMed  Google Scholar 

  5. Nguyen CT, Campbell SC. Staging of renal cell carcinoma: past, present, and future. Clin Genitourin Cancer. 2006;5(3):190–7.

    Article  PubMed  Google Scholar 

  6. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.

    Article  CAS  PubMed  Google Scholar 

  7. Katz DL, Zheng T, Holford TR, Flannery J. Time trends in the incidence of renal carcinoma: analysis of Connecticut tumor registry data, 1935–1989. Int J Cancer. 1994;58(1):57–63.

    Article  CAS  PubMed  Google Scholar 

  8. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    Article  PubMed  Google Scholar 

  9. Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009;18(3):801–7.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Romanenko A, Morell-Quadreny L, Nepomnyaschy V, Vozianov A, Llombart-Bosch A. Pathology and proliferative activity of renal-cell carcinomas (RCCS) and renal oncocytomas in patients with different radiation exposure after the Chernobyl accident in Ukraine. Int J Cancer. 2000;87(6):880–3.

    Article  CAS  PubMed  Google Scholar 

  11. Dhote R, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am. 2004;31(2):237–47.

    Article  CAS  PubMed  Google Scholar 

  12. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

    Article  CAS  PubMed  Google Scholar 

  13. Abouassaly R. Predictors of partial nephrectomy utilization and inequities of care in the treatment of renal cell carcinoma in Canada. [M.Sc. Thesis]. Toronto, Canada: University of Toronto; 2010.

    Google Scholar 

  14. Jun C, Zhishun X, Xianzhou J, Qiang F, Jin W. Association between age and clinical characteristics of renal cell carcinoma in adult patients. Int J Urol. 2006;13(5):515–9.

    Article  PubMed  Google Scholar 

  15. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.

    Article  CAS  PubMed  Google Scholar 

  16. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology. 2000;56(1):58–62.

    Article  CAS  PubMed  Google Scholar 

  17. Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol. 1996;14(4):216–22.

    CAS  PubMed  Google Scholar 

  18. Bach AM, Zhang J. Contemporary radiologic imaging of renal cortical tumors. Urol Clin North Am. 2008;35(4):593–604.

    Article  PubMed  Google Scholar 

  19. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33. discussion 33–4.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Skolarus TA, Serrano MF, Berger DA, et al. The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 2008;179(2):439–43.

    Article  PubMed  Google Scholar 

  21. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.

    Article  PubMed  Google Scholar 

  22. Eggener SE, Rubenstein JN, Smith ND, et al. Renal tumors in young adults. J Urol. 2004;171(1):106–10.

    Article  CAS  PubMed  Google Scholar 

  23. Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176(6 Pt 1):2391–5.

    Article  PubMed  Google Scholar 

  24. Novick AC, Campbell SC, et al. Guideline for management of the clinical stage 1 renal mass. Linthicum, MD: American Urological Association Education and Research; 2009.

    Google Scholar 

  25. Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology. 1996;48(5):692–5.

    Article  CAS  PubMed  Google Scholar 

  26. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol. 1995;13(4):254–61.

    CAS  PubMed  Google Scholar 

  27. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53(5):1003–11.

    Article  PubMed  Google Scholar 

  28. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy–a renaissance? J Urol. 2008;179(1):20–7.

    Article  PubMed  Google Scholar 

  29. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.

    Article  CAS  PubMed  Google Scholar 

  30. Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol. 2009;182(5):2132–6.

    Article  PubMed  Google Scholar 

  31. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275–84.

    Article  PubMed  Google Scholar 

  32. Gillett MD, Cheville JC, Karnes RJ, et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005;173(6):1893–6.

    Article  PubMed  Google Scholar 

  33. Komai Y, Fujii Y, Iimura Y, et al. Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology. 2011;77(4):842–7.

    Article  PubMed  Google Scholar 

  34. Verhoest G, Veillard D, Guille F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51(5):1298–304.

    Article  PubMed  Google Scholar 

  35. Jeong IG, Yoo CH, Song K, et al. Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival. J Urol. 2009;182(2):445–50.

    Article  PubMed  Google Scholar 

  36. Nguyen CT, Lane BR, Kaouk JH, et al. Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol. 2008;180(1):104–9.

    Article  PubMed  Google Scholar 

  37. Ficarra V, Schips L, Guille F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968–74.

    Article  PubMed  Google Scholar 

  38. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on Cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005;173(6):1889–92.

    Article  PubMed  Google Scholar 

  39. Salama ME, Guru K, Stricker H, et al. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol. 2005;173(5):1492–5.

    Article  CAS  PubMed  Google Scholar 

  40. Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2160–5.

    Article  PubMed  Google Scholar 

  41. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76(12):2543–9.

    Article  CAS  PubMed  Google Scholar 

  42. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604–14.

    Article  CAS  PubMed  Google Scholar 

  43. Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.

    Article  PubMed  Google Scholar 

  44. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162(6):1930–3.

    Article  CAS  PubMed  Google Scholar 

  45. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Lughezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009;182(4):1287–93.

    Article  PubMed  Google Scholar 

  47. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7.

    Article  PubMed  Google Scholar 

  48. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4):135–40.

    Article  PubMed  Google Scholar 

  49. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101(3):297–301.

    CAS  PubMed  Google Scholar 

  50. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–40.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Berger A, Brandina R, Atalla MA, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol. 2009;182(5):2172–6.

    Article  PubMed  Google Scholar 

  52. Hollingsworth JM, Miller DC, Dunn RL, Montgomery JS, Wolf Jr JS. Cost trends for oncological renal surgery: support for a laparoscopic standard of care. J Urol. 2006;176(3):1097–101.

    Article  PubMed  Google Scholar 

  53. Berdjis N, Hakenberg OW, Novotny V, Froehner M, Wirth MP. Treating renal cell cancer in the elderly. BJU Int. 2006;97(4):703–5.

    Article  PubMed  Google Scholar 

  54. Staehler M, Haseke N, Stadler T, et al. Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series. BJU Int. 2008;102(6):684–7.

    Article  PubMed  Google Scholar 

  55. Roos FC, Hampel C, Thuroff JW. Renal cancer surgery in the elderly. Curr Opin Urol. 2009;19(5):459–64.

    Article  PubMed  Google Scholar 

  56. Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S. The efficacy of laparoscopic radical nephrectomy for renal cell cancer in the elderly: an oncological outcome analysis. Int J Urol. 2008;15(7):577–81.

    Article  PubMed  Google Scholar 

  57. Hsu TH, Gill IS, Fazeli-Matin S, et al. Radical nephrectomy and nephroureterectomy in the octogenarian and nonagenarian: comparison of laparoscopic and open approaches. Urology. 1999;53(6):1121–5.

    Article  CAS  PubMed  Google Scholar 

  58. Lai FC, Kau EL, Ng CS, Fuchs GJ. Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol. 2007;21(11):1309–13.

    Article  PubMed  Google Scholar 

  59. Lowrance WT, Yee DS, Savage C, et al. Complications after radical and partial nephrectomy as a function of age. J Urol. 2010;183(5):1725–30.

    Article  PubMed  Google Scholar 

  60. Abouassaly R, Alibhai SM, Tomlinson GA, Urbach DR, Finelli A. The effect of age on the morbidity of kidney surgery. J Urol. 2011;186(3):811–6.

    Article  PubMed  Google Scholar 

  61. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

    Article  CAS  PubMed  Google Scholar 

  62. Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcomes in older patients at risk of vascular events: secondary analysis. PLoS Med. 2009;6(1):76–82.

    Article  Google Scholar 

  63. Rifkin DE, Shlipak MG, Katz RDP, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168(20):2212–8.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237–46.

    Article  CAS  PubMed  Google Scholar 

  65. Novick AC, Derweesh I. Open partial nephrectomy for renal tumours: current status. BJU Int. 2005;95 Suppl 2:35–40.

    Article  PubMed  Google Scholar 

  66. Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol. 1999;161(1):33–4.

    Article  CAS  PubMed  Google Scholar 

  67. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol. 2000;163(2):442–5.

    Article  CAS  PubMed  Google Scholar 

  68. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R, European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Southwest Oncology Group (SWOG), Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007;51(6):1606–15.

    Article  PubMed  Google Scholar 

  69. Stephenson AJ, Hakimi AA, Snyder ME, Russo P. Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol. 2004;171(1):130–4.

    Article  PubMed  Google Scholar 

  70. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.

    Article  CAS  PubMed  Google Scholar 

  71. Campbell SC, Novick AC, Streem SB, Klein EA. Management of renal cell carcinoma with coexistent renal artery disease. J Urol. 1993;150(3):808–13.

    CAS  PubMed  Google Scholar 

  72. Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML. Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol. 2005;174(3):855–8.

    Article  PubMed  Google Scholar 

  73. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.

    Article  PubMed  Google Scholar 

  74. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.

    Article  PubMed  Google Scholar 

  75. Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int. 2007;99(5 Pt B):1265–70.

    Article  PubMed  Google Scholar 

  76. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol. 2008;179(4):1277–81.

    Article  PubMed  Google Scholar 

  77. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma–a meta-analysis and review. J Urol. 2008;179(4):1227–33.

    Article  PubMed  Google Scholar 

  78. Mindrup SR, Pierre JS, Dahmoush L, Konety BR. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int. 2005;95(1):31–3.

    Article  PubMed  Google Scholar 

  79. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8.

    Article  PubMed  Google Scholar 

  80. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.

    Article  PubMed  Google Scholar 

  81. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13):3119–26.

    Article  PubMed  Google Scholar 

  82. Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM. What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int. 2011;108(8 Pt 2):E223–31.

    Article  PubMed  Google Scholar 

  83. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80(7):1198–220.

    Article  CAS  PubMed  Google Scholar 

  84. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    Article  CAS  PubMed  Google Scholar 

  85. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  86. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.

    Article  PubMed  Google Scholar 

  87. Kader AK, Tamboli P, Luongo T, et al. Cytoreductive nephrectomy in the elderly patient: the M.D. Anderson Cancer Center experience. J Urol. 2007;177(3):855–60.

    Article  PubMed  Google Scholar 

  88. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  PubMed  Google Scholar 

  89. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    Article  CAS  PubMed  Google Scholar 

  90. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  92. Porta C, Calvo E, Climent MA, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial. Eur Urol. 2012;61(4):826–33.

    Article  CAS  PubMed  Google Scholar 

  93. Hutson TE, Bukowski RM, Rini BI, et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. J Clin Oncol. 2011;29:4604. suppl; abstrt.

    Article  Google Scholar 

  94. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.

    CAS  PubMed  Google Scholar 

  95. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.

    Article  CAS  PubMed  Google Scholar 

  96. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24(19):3101–6.

    Article  PubMed  Google Scholar 

  97. Muramaki M, Miyake H, Sakai I, et al. Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pT1 renal cell carcinoma. Int J Urol. 2011;18(2):121–5.

    Article  PubMed  Google Scholar 

  98. Denzinger S, Otto W, Burger M, et al. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol. 2007;5:16.

    Article  PubMed Central  PubMed  Google Scholar 

  99. Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol. 2009;181(2):506–11.

    Article  PubMed Central  PubMed  Google Scholar 

  100. Sun M, Abdollah F, Bianchi M, et al. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. Eur Urol. 2011;60(6):1152–9.

    Article  PubMed  Google Scholar 

  101. Cloutier V, Capitanio U, Zini L, et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol. 2008;56(6):998–1003.

    Article  PubMed  Google Scholar 

  102. Corman JM, Penson DF, Hur K, et al. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int. 2000;86(7):782–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Institute, University Hospitals Case Medical Center, 11100 Euclid Avenue, Mailstop LKS 5046, Office 4565, Cleveland, OH, 44106, USA

    Robert Abouassaly M.D., M.Sc., F.R.C.S.C.

  2. Urology, Cleveland Clinic, Room Q10-120, 9500 Euclid Avenue, Cleveland, OH, 44022, USA

    Steven C. Campbell M.D., Ph.D.

Authors
  1. Robert Abouassaly M.D., M.Sc., F.R.C.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven C. Campbell M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Abouassaly M.D., M.Sc., F.R.C.S.C. .

Editor information

Editors and Affiliations

  1. Department of Urology and the Landon Center on Aging, The University of Kansas, Kansas City, Kansas, USA

    Tomas Lindor Griebling

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abouassaly, R., Campbell, S.C. (2014). Kidney Cancer. In: Griebling, T. (eds) Geriatric Urology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9047-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9047-0_19

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-9046-3

  • Online ISBN: 978-1-4614-9047-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation